Radiological staging of ovarian cancer: Imaging findings and contribution of CT and MRI

European Radiology

Volumn 17, Issue 12, 2007, Pages 3223-3235

  Forstner, Rosemarie ^a  

^a Universitätsinstitut für Radiodiagnostik ^*  (Austria)

Author keywords

Biopsy in peritoneal carcinomatosis; Non resectability; Ovarian cancer staging; Ovarian malignancy

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; TUMOR MARKER;

ADVANCED CANCER; ARTICLE; CANCER INCIDENCE; CANCER RISK; CANCER STAGING; CANCER STATISTICS; CARCINOMATOUS PERITONITIS; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DIAGNOSTIC IMAGING; DIAPHRAGM; FEMALE GENITAL TRACT TUMOR; HUMAN; IMAGE ANALYSIS; INTRAOPERATIVE PERIOD; LAPAROTOMY; LIVER; LYMPH NODE METASTASIS; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PATIENT CARE; PATIENT REFERRAL; PATIENT SELECTION; PERITONEUM METASTASIS; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; SURGICAL TECHNIQUE; TEAMWORK; TREATMENT PLANNING;

BIOPSY; CONTRAST MEDIA; FEMALE; HUMANS; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; NEOPLASM STAGING; OVARIAN NEOPLASMS; PATIENT SELECTION; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 36349037151     PISSN: 09387994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00330-007-0736-5     Document Type: Article

References (64)

1. Ozols RF (2005) Treatment goals in ovarian cancer. Int J Gynecol Cancer 5(suppl 1):3-11
2. Spencer JA (2005) A multidisciplinary approach to ovarian cancer at diagnosis. BJR 78:S94-S10
3. Parkin DM, Bray F, Pisani F, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108
4. Colombo N, Van Gorp T, Parma G et al (2006) Ovarian cancer. Crit Rev Oncol/Hematol 60:159-179
5. Pignata S, Vermorken JB (2004) Ovarian cancer in the elderly. Crit Rev Oncol/Hematol 49:77-86
6. Ozols RF, Schwartz PE, Eifel PJ (2001) Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma. In: De Vita VT Jr, Hellman S, Rosenberg SA (eds) Cancer. Principles and practice of oncology, 6th edn. Lippincott Williams & Wilkins, Philadelphia, pp 1597-1632
7. Clark TG, Stewart ME, Altmann DG et al (2001) A prognostic model for ovarian cancer. Br J Cancer 85:944-952
8. Holschneider CH, Berek JS (2000) Ovarian cancer: Epidemiology, biology, and prognostic factors. Semin Surg Oncol 19:3-10
9. Seidman JD, Russell P, Kurman RJ (2002) Surface epithelial tumors of the ovary. In: Kurman RJ (ed) Blaustein's pathology of the female genital tract. Springer Verlag, Berlin Heidelberg New York, pp 791-904
10. Ries LAG, Eisner MP, Kosary CL et al (2002) SEER a cancer statistics review, 1973-1999 http://seer.cancer.gov/csr/1973-199/ Bethesda, MD: National cancer institute
11. Berchuck A, Iversen ES, Lancaster JM et al (2005) Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res 11:3686-3696
12. Vaisbuch E, Dgani R, Ben-Arie A et al (2005) The role of laparoscopy in ovarian tumors of low malignant potential and early-stage ovarian cancer. Obstet Gynecol Surv 60:326-330
13. Ovarian cancer. American cancer society. http://www.cancer.org
14. Staging announcement: FIGO cancer committee (1986) Gynecol Oncol 25:383-385
15. Carnino F, Fuda GC, Ciccone G et al (1997) Significance of lymph node sampling in epithelial carcinoma of the ovary. Gynecol Oncol 65:467-472
16. Javitt MC, Fleischer AC, Andreotti RF et al (2005) Staging and Follow-up of ovarian cancer. American college of Radiology. http://www.acr.org recommendations
17. Low RN, Duggan B, Barone RM et al (2005) Treated ovarian cancer: MR imaging, laparotomy reassessment, and serum CA-125 values compared with clinical outcome at 1 year. Radiology 235:918-926
18. Forstner R, Kinkel K (2006) Adnexal masses: Characterization of benign ovarian lesions. In: Hamm B, Forstner R (eds) CT and MRI of the female pelvis. Springer Verlag, Berlin Heidelberg New York, pp 195-230
19. Pannu H, Bristow RE, Montz FJ et al (2003) Multidetector CT of peritoneal carcinomatosis from ovarian cancer. RadioGraphics 23:687-701
20. Woodward PJ, Hosseinzadeh K, Saenger JS (2004) Radiologic staging of ovarian carcinoma with pathologic correlation. From the archives of the AFIP. Radiographics 24:225-246
21. Forstner R, Hricak H, Occhipinti K et al (1995) Ovarian cancer: Staging with CT and MRI. Radiology 197:619-626
22. Tempany CM, Zou KH, Silverman et al (2000) Staging of advanced ovarian cancer: Comparison of imaging modalities-report from the Radiology Oncology Group. Radiology 215:761-767
23. Coakley FV (2002) Staging ovarian cancer: Role of imaging. Radiol Clin N Am 40:609-636
24. Yoshida Y, Kurokawa T, Kawahara K et al (2003) Incremental benefits of FDG Positron Emissions Tomography over CT alone for the preopetative staging of ovarian cancer. AJR 182:227-233
25. Forstner R (2006) CT and MRI in ovarian carcinoma. In: Hamm B, Forstner R (eds) CT and MRI of the female pelvis. Springer Verlag, Berlin Heidelberg New York, pp 231-261
26. Kurtz AB, Tsimikas JV, Tempany CMC et al (1999) Diagnosis and staging og ovatian cancer:cOmparative values of Doppler and conventional US, Ct, and MR imaging correlated with surgery and histopathologgic analysis-report of the Radiology diagnostic oncology group. Radiology 212:19-27
27. Bristow RE, del Carmen GM, Pannu HK et al (2003) Clinically occult recurrent ovarial cancer: Patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol Oncol 90:519-528
28. Sironi S, Messa C, Mangili G et al (2004) Integrated FDG PET/CT in patients with persistent ovarian cancer: Correlation with histologic findings. Radiology 233:433-440
29. Ricke J, Sehouli J, Hach C et al (2003) Prospective evaluation of contrast-enhanced MRI in the depiction of peritoneal spread in primary or recurrent ovarian cancer. Eur Radiol 13:943-949
30. Mitchell DG, Hill MC, Hill S et al (1986) Serous carcinoma of the ovary: CT identification of metastatic calcified implants. Radiology 158:649-652
31. Low RN, Barone RM, Lacey C et al (1997) Peritoneal tumor: MRI with dilute oral Barium and intravenous Gadolinium-containing contrast agents compared with unenhanced MRI and CT. Radiology 204:513-520
32. Brasanac D, Boricic I, Todorovic V et al (2005) Umbilical metastasis (Sister Josef's nodule) as a first sign of disseminated ovarian carcinoma: Comparative immhunohistochemical analysis and its metastases. Int J Gynecol Cancer 15:377-381
33. Low RN, Chen SC, Barone R et al (2003) Distinguishing benign from malignant bowel obstruction in patients with malignancy: Findings at MRI. Radiology 228:157-165
34. Coakley FV, Choi PH, Gougoutas CA et al (2002) Peritoneal metastases: detection with spiral CT in patients with ovarian cancer. Radiology 223:495-499
35. Fujii S, Matsusue E, Nakanishi J et al (2006) Clinical utility of diffusion -weighted MR imaging in the diagnosis of ovarian tumor and peritoneal dissemination. RSNA abstract book p 750
36. Chen SS, Lee L (1983) Incidence of para-aortic and pelvic lymph node metastases in epithelial carcinoma of the ovary. Gynecol Oncol 16:95-100
37. Benedetti-Panici P, Greggi S, Maneschi F et al (1993) Anatomical and pathological study of retroperitoneal nodes in epithelial ovarian cancer. Gynecol Oncol 51:150-154
38. Rockall AG, Sohaib SA, Harisinghani MK et al (2005) Diagnostic performance of nanoparticle-enhanced MRI in the diagnosis of lymph node metastases in patients with endometrial and cervical cancer. J Clin Oncol 12:2813-2821
39. Bristow RE, Giuntoli RL, Pannu HK et al (2005) Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes. Gynecol Oncol 99:294-300
40. Aronberg DJ, Peterson RR, Glazer HS et al (1986) Superior diaphragmatic lymph nodes: CT assessment. J Comput Assist Tomogr 10:937-941
41. Holloway BJ, Gore ME, Hern RP et al (1997) The significance of paracardiac lymph node enlargement in ovarian cancer. Clin Radiol 52:692-69
42. Sirlin CB, Casola G, Brown AM et al (2001) US of blunt abdominal trauma: importance of free fluid in women of reproductive age. Radiology 219:229-235
43. Shen-Gunther J, Mannel RS (2002) Ascites as a predictor of ovarian malignancy. Gynecol Oncol 87:77-83
44. Jacobs I, Bast RC (1989) The CA-125 tumour-associated antigen: A review of the literature. Human Reprod 4:1-12
45. Togashi K (2003) Ovarian cancer: The role of US, CT and MRI. Europ Radiol 13(Suppl 4):L87-L104
46. Bohm-Velez M, Mendelson E, Bree R et al (2000) Ovarian cancer screening. American College of Radiology. ACR Appropriateness criteria. Radiology 215:861-871
47. Zurawski VR, Knapp RC, Einhorn N et al (1988) An initial analysis of preoperative Ca 125 levels in patients with early stage ovarian carcinoma. Gynecol Oncol 30:7-14
48. Kinkel K, Ying L, Mehdizade A et al (2005) Indeterminate ovarian mass at US: Incremental value of second imaging test for characterization- Meta-analysis and Bayesian Analysis. Radiology 236:85-94
49. Marhom E, Cohen I (2007) Fertility preservation options for women with malignancies. Obstet Gynecol Surv 62:58-72
50. Quayyum A, Coakley FV, Westphalen AC et al (2005) Role of CT and MRI in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer. Gyneco Oncol 96:301-306
51. Du Bois A, Rochon J, Lamparter C et al (2005) The quality assurance program of the AGO Organkommission OVAR QS- Ovar. Pattern of care and reality in Germany. Zentralblatt Gynäkol 127:9-17
52. Giede KC, Kieser K, Dodge J, Rosen B (2005) Who should operate on patients with ovarian cancer. An evidence based review. Gynecol Oncol 99:447-461
53. Fischer D, Cordes T, Schroer A et al (2006) Die radikale Primäroperation des fortgeschrittenen Ovarialkarzinoms. Gynäkologe 39:762-767
54. Aletti GD, Dowdi SC, Gostout BS et al (2006) Aggressive surgical effort and improved survival in advanced stage ovarian cancer. Obstet Gynecol 107:77-85
55. Ansquer Y, Leblanc E, Clough K et al (2001) Neoadjuvant chemotherapy for unresectable ovarian carcinoma. Cancer 91:2329-2334
56. Schwartz PE, Chambers JT, Makuch R (1994) Neoadjuvant chemotherapy for advanced ovarian cancer. Gynecol Oncol 53:33-37
57. Bristow RE, Tomacruz RS, Armstrong DK et al (2002) Survival effects of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta analysis. J Clin Oncol 20:1248-1259
58. Huober J, Meyer A, Wagner U, Wallwiener D (2002) The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer. Cancer Res Clin Oncol 128:153-160
59. Van der Burg ME (2001) Advanced ovarian cancer. Curr Treat Options Oncol 2:109-118
60. Nelson BE, Rosenfield AT, Schwartz PE (1993) Preoperative abdominopelvic CT prediction of optimal cytoreduction in epithelial ovarian cancer. J Clin Oncol 11:166-172
61. Bristow RE, Duska LR, Lambrou NC et al (2000) A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer 89:1532-1540
62. Spencer JA, Anderson K, Takeuchi E et al (2006) Radiological findings and image guided biopsy in women with peritoneal carcinomatosis and a history of breast cancer. ESUR abstract book p 22
63. Spencer JA, Swift SE, Wilkinson N et al (2001) Peritoneal carcinomatosis: Image guided peritoneal core biopsy for tumor type and patient management 221:173-177
64. Hewitt MJ, Hall GD, Wilkinson N et al (2006) Image-guided biopsy in women with breast cancer presenting with peritoneal carcinomatosis. Int J Gynecol Cancer (2006) 16(Suppl 1):108-110